Abstract
Human carbonyl reductase (CBR) activity accounts for a significant fraction of the metabolism of endogenous and xenobiotic carbonyl compounds. It is possible that genetic polymorphisms in CBR1 and CBR3 are key for the wide interindividual variability in the disposition of CBR drug substrates. We pinpointed a single nucleotide polymorphism in CBR3 (CBR3 V244M) that encodes for a V244 to M244 change. Blacks showed a higher frequency of the M244 allele (q = 0.51, n = 49) than did whites (q = 0.31, n = 70; p = 0.003). In addition, DNA variation panels from 10 ethnic groups presented a wide range of CBR3 V244M genotype distributions. Kinetic experiments with the recombinant CBR3 protein variants and menadione revealed that CBR3 M244 has significantly higher Vmax than does CBR3 V244 (Vmax CBR3 M244 = 40.6 ± 1.3 μmol/min · mg versus Vmax CBR3 V244 = 19.6 ± 2.0 μmol/min · mg, p = 0.002). In contrast, both isoforms presented similar Km values (Km CBR3 M244 = 22.9 ± 2.9 μM versus Km CBR3 V244 = 24.6 ± 3.2 μM, p = 0.43). Assays with NADP(H) demonstrated a higher VmaxNADP(H) (1.6-fold) and increased catalytic efficiency (VmaxNADP(H)/KmNADP(H)) for CBR3 M244 compared with CBR3 V244 (p = 0.013). Comparative three-dimensional analyses based on the structure of the homologous porcine carbonyl reductase suggested that the V244M substitution is positioned in a region critical for interactions with the NADP(H) cofactor. These studies demonstrate that the common CBR3 V244M polymorphism encodes for CBR3 isoforms with distinctive enzymatic properties.
Footnotes
-
This work was supported by grants from The Kapoor Foundation and from the Lance Armstrong Foundation (principal investigator, Smita Bhatia), and by National Institutes of Health Grant CA16056.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.104.002006.
-
ABBREVIATIONS: CBR, carbonyl reductase; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; PTCR, porcine testicular carbonyl reductase.
- Received September 16, 2004.
- Accepted November 9, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|